Prof Dr Özgül ALPER, Ph.D.

Fuzbien Technology Institute,Inc., Rockville, MD, USA
**Antalya Bilim University, Faculty of Dentistry, Antalya, Turkey*
oalper8@yahoo.com; ozgul.alper@antalya.edu.tr

ACADEMIC QUALIFICATIONS

Hacettepe University Faculty of Science, Biology (Bachelor of Science) 1986 - 1990
Hacettepe University Faculty of Medicine, Medical Biology (MSc Degree) 1990 - 1993
Akdeniz University Faculty of Medicine, Medical Biology & Genetics (PhD Degree) 1993-1999
National Institutes of Health, NIDCD, Postdoctoral fellow 1999-2000
Georgetown University, Faculty of Medicine, Institute for Molecular and Human Genetics, Postdoctoral fellow 2000-2004
Akdeniz University Faculty of Medicine, Medical Biology & Genetics, Associate Professor, Clinical Laboratory Responsibility, Medical Genetics Diagnostic Center 2004-2012
Akdeniz University Faculty of Medicine, Medical Biology & Genetics, Professor, Clinical Laboratory Responsibility, Medical Genetics Diagnostic Center 2012-2019

Present positions held:

- 2021 - present: Consultant, American Diagnostics & Therapeutics, LLC (ADxRx), MD, USA
- 2020 - present: R&D Director, Fuzbien Technology Institute Inc. (FTI), MD, USA
- 2020 - Emeritus Professor, Medical Biology & Genetics from Akdeniz University, Faculty of Medicine, Antalya, Turkey

Present research activities:

- Ongoing research project related with the circulating biomarkers in pancreatic cancer progression. This project belongs to ADxRx Bioctech Company. Dr Alper has a consultant and researcher role for the molecular genetic analysis of the selected circulating biomarkers.
- Ongoing nanotechnology platform based research project related between the biotech companies of FTI and ADxRx. Dr Alper has a researcher role for the related project. Nanotechnology platform will be applied for the novel pancreatic cancer biomarkers with the use of FTI's nanodevice. Currently, FTI's Nanodevice ultrastructure is under progress in Seoul, Korea.

Responsibilities in Research Projects

Dr. Alper is a consultant of several research projects and networks at Korean and US biotech companies. She is interested in nanotechnology for biomedical applications, biomarkers in correlation with genomic and molecular genetic technology for early detection of solid tumor cancers. She is also responsible of a number of research contracts with biotech companies, and research centers.

Referee's activity

Dr. Alper is currently serving at international level as a reviewer of research projects and scientific articles, in particular for Journals such as: *Genes and Genomics, Human Genetics, European Medical Journal, Hereditas*, etc.

Scientific Publications

Dr. Alper is co-authored of more than 20 scientific publications, including 6 books, 4 book chapters.
H index: 13 *Orcid ID: 0000-0003-1536-2111* *Res ID: D-3961-2012*

10 Selected recent papers

- Review of Diabetes Mellitus in Relation to Pancreatic Cancer. O Alper, SN Ahn, M Knight and **OM Alper**. *Clinical Medical Case Reports and Reviews.* **1**: 1–6, 2021. doi: 10.31038/CMCRR.2021111.
- Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Brown P; RELISH Consortium, Zhou Y. *Database (Oxford).* 2019 Jan **1**;2019:baz085. doi: 10.1093/database/baz085.
- Coronal craniosynostosis due to TCF12 mutations in patients from Turkey. Yilmaz E, Mihci E, Nur B, **Alper OM.** *Am J Med Genet A.* 2019 Nov;**179**(11):2241-2245. doi:10.1002/ajmg.a.61311.
- A novel AXIN2 gene mutation in sagittal synostosis.Yilmaz E, Mihci E, Guzel Nur B, **Alper OM.** *Am J Med Genet A.* 2018 Sep;**176**(9):1976-1980. doi: 10.1002/ajmg.a.40373.
- Genetic analysis of Mayer-Rokitansky-Kuster-Hauser syndrome in a large cohort of families.Williams LS, Demir Eksi D, Shen Y, Lossie AC, Chorich LP, Sullivan ME, Phillips JA 3rd, Erman M, Kim HG, **Alper OM**, Layman LC. *Fertil Steril.* 2017 Jul;**108**(1):145-151.e2. doi: 10.1016/j.fertnstert.2017.05.017.
- MPZL2 is a novel gene associated with autosomal recessive nonsyndromic moderate hearing loss. Bademci G, Abad C, Incesulu A, Rad A, **Alper O**, Kolb SM, Cengiz FB, Diaz-Horta O, Silan F, Mihci E, Ocak E, Najafi M, Maroofian R, Yilmaz E, Nur BG, Duman D, Guo S, Sant DW, Wang G, Monje PV, Haaf T, Blanton SH, Vona B, Walz K, Tekin M. *Hum Genet.* 2018 Jul;**137**(6-7):479-486. doi: 10.1007/s00439-018-1901-4.
- Clinicogenetic study of Turkish patients with syndromic craniosynostosis and literature review. Nur BG, Pehlivanoğlu S, Mıhçı E, Calışkan M, Demir D, **Alper OM**, Kayserili H, Lüleci G. *Pediatr Neurol.* 2014. May;**50**(5):482-90. doi: 10.1016/j.pediatrneurol.2014.01.023.
- Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line. Pack SD, **Alper OM**, Stromberg K, Augustus M, Ozdemirli M, Miermont AM, Klus G, Rusin M, Slack R, Hacker NF, Ried T, Szallasi Z, Alper O. *Cancer Res.* 2004 Feb 1;**64**(3):789-94. doi: 10.1158/0008-5472.can-03-1982.
- Identification of novel and rare mutations in California Hispanic and African American cystic fibrosis patients. **Alper OM**, Wong LJ, Young S, Pearl M, Graham S, Sherwin J, Nussbaum E, Nielson D, Platzker A, Davies Z, Lieberthal A, Chin T, Shay G, Hardy K, Kharrazi M. *Hum Mutat.* 2004 Oct;**24**(4):353. doi: 10.1002/humu.9281.
- Two novel null mutations in a Taiwanese cystic fibrosis patient and a survey of East Asian *CFTR* mutations. Wong LJ, **Alper OM**, Wang BT, Lee MH, Lo SY. *Am J Med Genet A.* 2003 Jul 15;**120A**(2):296-8. doi:10.1002/ajmg.a.20039.

Updated Oct,2021